Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAB NASDAQ:INBX NASDAQ:MESO NASDAQ:UPB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$70.95+2.4%$61.18$11.40▼$72.36$2.07B0.79808,679 shs89,705 shsINBXInhibrx Biosciences$132.42+3.4%$80.33$10.84▼$155.29$1.93B3.88277,480 shs145,284 shsMESOMesoblast$15.53-1.6%$15.25$9.88▼$21.50$2.01B2.09241,948 shs49,894 shsUPBUpstream Bio$9.16+0.4%$9.05$7.25▼$33.68$497.94M1.281.09 million shs45,481 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+4.09%+5.12%+20.48%+43.64%+235.23%INBXInhibrx Biosciences-0.52%-1.94%+101.67%+55.18%+939.09%MESOMesoblast+0.32%+3.75%+6.62%-7.06%+39.73%UPBUpstream Bio-2.98%-4.10%-4.00%-68.96%+5.07%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$70.95+2.4%$61.18$11.40▼$72.36$2.07B0.79808,679 shs89,705 shsINBXInhibrx Biosciences$132.42+3.4%$80.33$10.84▼$155.29$1.93B3.88277,480 shs145,284 shsMESOMesoblast$15.53-1.6%$15.25$9.88▼$21.50$2.01B2.09241,948 shs49,894 shsUPBUpstream Bio$9.16+0.4%$9.05$7.25▼$33.68$497.94M1.281.09 million shs45,481 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+4.09%+5.12%+20.48%+43.64%+235.23%INBXInhibrx Biosciences-0.52%-1.94%+101.67%+55.18%+939.09%MESOMesoblast+0.32%+3.75%+6.62%-7.06%+39.73%UPBUpstream Bio-2.98%-4.10%-4.00%-68.96%+5.07%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.85Moderate Buy$76.187.38% UpsideINBXInhibrx Biosciences 2.33Hold$150.0013.28% UpsideMESOMesoblast 2.33HoldN/AN/AUPBUpstream Bio 2.60Moderate Buy$39.00326.00% UpsideCurrent Analyst Ratings BreakdownLatest UPB, MESO, INBX, and ANAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026ANABAnaptysBio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/4/2026ANABAnaptysBio Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$95.00 ➝ $93.004/28/2026ANABAnaptysBio Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$66.00 ➝ $85.004/24/2026INBXInhibrx Biosciences Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/22/2026ANABAnaptysBio BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$79.00 ➝ $63.004/21/2026MESOMesoblast Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026ANABAnaptysBio UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$90.00 ➝ $60.004/9/2026INBXInhibrx Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold4/8/2026INBXInhibrx Biosciences Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$150.003/31/2026ANABAnaptysBio Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$67.00 ➝ $95.003/30/2026ANABAnaptysBio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$66.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$234.60M8.80N/AN/A$1.34 per share52.94INBXInhibrx Biosciences$1.30M1,488.20N/AN/A$0.55 per share240.76MESOMesoblast$17.20M116.92N/AN/A$4.67 per share3.33UPBUpstream Bio$2.85M174.81N/AN/A$6.29 per share1.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$13.23M-$0.52N/AN/AN/A-5.64%-1,101.24%-3.59%N/AINBXInhibrx Biosciences-$140.05M-$9.04N/AN/AN/AN/A-269.56%-71.94%5/13/2026 (Estimated)MESOMesoblast-$102.14M-$0.54N/AN/AN/AN/AN/AN/AN/AUPBUpstream Bio-$143.44M-$2.67N/AN/AN/A-5,026.03%-36.48%-35.38%N/ALatest UPB, MESO, INBX, and ANAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026INBXInhibrx Biosciences-$1.6750N/AN/AN/AN/AN/A3/26/2026Q4 2025UPBUpstream Bio-$0.73-$0.7860-$0.0560-$0.78$0.52 million$0.67 million3/19/2026Q4 2025INBXInhibrx Biosciences-$2.08-$2.11-$0.03-$2.11N/AN/A3/3/2026Q4 2025ANABAnaptysBio$0.89$1.58+$0.69$1.58$87.09 million$108.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A9.079.07INBXInhibrx Biosciences12.583.933.93MESOMesoblast0.101.581.41UPBUpstream BioN/A26.1526.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/AINBXInhibrx Biosciences82.46%MESOMesoblast1.43%UPBUpstream BioN/AInsider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%INBXInhibrx BiosciencesN/AMESOMesoblast18.80%UPBUpstream Bio13.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10029.10 million19.35 millionOptionableINBXInhibrx Biosciences16614.61 millionN/AOptionableMESOMesoblast80129.46 million105.12 millionOptionableUPBUpstream Bio3854.42 million47.04 millionN/AUPB, MESO, INBX, and ANAB HeadlinesRecent News About These CompaniesJennison Associates LLC Makes New Investment in Upstream Bio, Inc. $UPBMay 3 at 6:20 AM | marketbeat.com773,148 Shares in Upstream Bio, Inc. $UPB Acquired by Pictet Asset Management Holding SAMay 2, 2026 | marketbeat.comUpstream Bio (UPB) to Release Quarterly Earnings on TuesdayApril 28, 2026 | marketbeat.comUpstream Bio, Inc. (NASDAQ:UPB) Given Consensus Recommendation of "Moderate Buy" by BrokeragesApril 22, 2026 | marketbeat.comUpstream Bio stellt neue Daten zu Verekitug auf Fachkonferenz vorApril 17, 2026 | de.investing.comUpstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International ConferenceApril 17, 2026 | globenewswire.comUpstream Bio (UPB) price target decreased by 10.31% to 44.37April 10, 2026 | msn.comValidating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–RewardApril 7, 2026 | tipranks.comTruist senkt Kursziel für Upstream Bio wegen verzögertem StudienzeitplanApril 2, 2026 | de.investing.comEvercore ISI stuft Upstream Bio wegen fehlender kurzfristiger Katalysatoren herabMarch 27, 2026 | de.investing.comUpstream Bio plant Phase-3-Studien für Asthma-Medikament ab Q1 2027March 26, 2026 | de.investing.comUpstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 26, 2026 | globenewswire.comUpstream Bio: CFO Gray veräußert Aktien im Wert von 7.915 US-DollarMarch 18, 2026 | de.investing.comUpstream Bio Reports Positive Phase 2 VIBRANT Trial Results for Verekitug in Chronic Rhinosinusitis with Nasal PolypsMarch 1, 2026 | quiverquant.comQUpstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual MeetingMarch 1, 2026 | globenewswire.comUpstream Bio präsentiert neue Studiendaten zu Verekitug auf AAAAI-KongressFebruary 26, 2026 | de.investing.comUpstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026February 26, 2026 | globenewswire.comUpstream Bio to Participate in Upcoming March Investor ConferencesFebruary 25, 2026 | globenewswire.comCompanies Like Upstream Bio (NASDAQ:UPB) Are In A Position To Invest In GrowthFebruary 15, 2026 | finance.yahoo.comUpstream Bio's selloff may be 'overdone,' but analyst highlights asthma drug's competitive edge concernsFebruary 13, 2026 | msn.comUpstream Bio: Hold Rating As Verekitug Faces Competition Among Latest Asthma DataFebruary 13, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUPB, MESO, INBX, and ANAB Company DescriptionsAnaptysBio NASDAQ:ANAB$70.94 +1.67 (+2.40%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Inhibrx Biosciences NASDAQ:INBX$132.42 +4.30 (+3.36%) As of 11:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Mesoblast NASDAQ:MESO$15.53 -0.26 (-1.62%) As of 11:19 AM Eastern This is a fair market value price provided by Massive. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Upstream Bio NASDAQ:UPB$9.15 +0.04 (+0.38%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
